The Role of Aprepitant in Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery

  • Isaac W. Therneau
  • Erin E. Martin
  • Juraj Sprung
  • Todd A. Kellogg
  • Darrell R. Schroeder
  • Toby N. Weingarten
Original Contributions

Abstract

Background

Postoperative nausea and vomiting (PONV) is common with bariatric surgery. We examined the PONV rate in bariatric surgical patients who received triple antiemetic prophylaxis (dexamethasone, droperidol, and ondansetron) with and without antiemetic aprepitant.

Methods

Medical records of female patients undergoing laparoscopic bariatric surgery from January 1, 2014, to July 28, 2016, were reviewed for PONV episodes during 48 postoperative hours.

Results

In total, 338 patients received triple antiemetic, of whom 172 (51%) also received aprepitant. Rates of PONV in the postanesthesia care unit (PACU) among patients with and without aprepitant therapy were 11 vs 17% (P = .09). Within 1 h after PACU discharge, fewer patients in the aprepitant group had PONV (19 vs 31%; odds ratio [OR] [95% CI], 0.5 [0.30–0.80]; P = .007). During the first 48 postoperative hours, PONV rates were similar between the groups (68 and 66%; P = .73), but fewer emesis episodes occurred in the aprepitant group (6 vs 13%; OR [95% CI], 0.45 [0.21–0.95]; P = .04). Analyses were also performed with a subset of patients matched on propensity for receiving aprepitant. In this subset, OR estimates quantifying aprepitant effect on PONV were similar to those obtained from multivariable regression analyses.

Conclusion

Addition of aprepitant to a multimodal antiemetic prophylactic regimen may be associated with significant reduction of PONV during early recovery and potentially with reduced incidence of vomiting during the first 48 postoperative hours. The high PONV rate in the first 48 postoperative hours is suggestive that introduction of scheduled anti-PONV prophylactic treatment may be desirable.

Keywords

Aprepitant Bariatric surgery Postoperative nausea and vomiting 

Abbreviations

CI

Confidence interval

NK-1

Neurokinin-1

OR

Odds ratio

OSA

Obstructive sleep apnea

PACU

Postanesthesia care unit

PONV

Postoperative nausea and vomiting

SD

Standard deviation

References

  1. 1.
    Weingarten TN, Hawkins NM, Beam WB, et al. Factors associated with prolonged anesthesia recovery following laparoscopic bariatric surgery: a retrospective analysis. Obes Surg. 2015;25(6):1024–30.Google Scholar
  2. 2.
    Sinha AC, Singh PM, Williams NW, et al. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24(2):225–31.Google Scholar
  3. 3.
    Gan TJ, Diemunsch P, Habib AS, et al. Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113.Google Scholar
  4. 4.
    Apfel CC, Laara E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91(3):693–700.Google Scholar
  5. 5.
    Moon HY, Baek CW, Choi GJ, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014;14:68.Google Scholar
  6. 6.
    Weingarten TN, Gurrieri C, McCaffrey JM, et al. Acute kidney injury following bariatric surgery. Obes Surg. 2013;23(1):64–70.Google Scholar
  7. 7.
    White PF, O’Hara JF, Roberson CR, et al. The impact of current antiemetic practices on patient outcomes: a prospective study on high-risk patients. Anesth Analg. 2008;107(2):452–8.Google Scholar
  8. 8.
    Apfel CC, Korttila K, Abdalla M, et al. Impact investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441–51.Google Scholar
  9. 9.
    Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int. 1985;7(2):191–211.Google Scholar
  10. 10.
    Gralla RJ, Roila F, Tonato M, et al. The 2004 Perugia antiemetic consensus guideline process: methods, procedures, and participants. Support Care Cancer. 2005;13(2):77–9.Google Scholar
  11. 11.
    Gan TJ, Apfel CC, Kovac A, et al. Aprepitant Ponv study group. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104(5):1082–9.Google Scholar
  12. 12.
    Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1(2):121–9.Google Scholar
  13. 13.
    Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg. 2011;112(4):813–8.Google Scholar
  14. 14.
    Lee SJ, Lee SM, Kim SI, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol. 2012;63(3):221–6.Google Scholar
  15. 15.
    Flemons WW. Clinical practice: obstructive sleep apnea. N Engl J Med. 2002;347(7):498–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Weingarten TN, McGlinch BP, Liedl L, et al. Intranasal nicotine increases postoperative nausea and is ineffective in reducing pain following laparoscopic bariatric surgery in tobacco-naive females: a randomized, double blind trial. Obes Surg. 2015;25(3):506–13.Google Scholar
  17. 17.
    Weingarten TN, Bergan TS, Narr BJ, et al. Effects of changes in intraoperative management on recovery from anesthesia: a review of practice improvement initiative. BMC Anesthesiol. 2015;15:54.Google Scholar
  18. 18.
    Vallejo MC, Phelps AL, Ibinson JW, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg. 2012;129(2):519–26.Google Scholar
  19. 19.
    Gan TJ, Gu J, Singla N, et al. Rolapitant investigation group. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg. 2011;112(4):804–12.Google Scholar
  20. 20.
    Pierre S, Whelan R. Nausea and vomiting after surgery. Contin Educ Anaesth Crit Care Pain. 2013;13(1):28–32.CrossRefGoogle Scholar
  21. 21.
    Reference withheld for anonymous review.Google Scholar
  22. 22.
    Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016 Feb;92(1084):87–98.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Isaac W. Therneau
    • 1
  • Erin E. Martin
    • 1
  • Juraj Sprung
    • 1
  • Todd A. Kellogg
    • 2
  • Darrell R. Schroeder
    • 3
  • Toby N. Weingarten
    • 1
  1. 1.Department of Anesthesiology and Perioperative MedicineMayo ClinicRochesterUSA
  2. 2.Division of Subspecialty General SurgeryMayo ClinicRochesterUSA
  3. 3.Division of Biomedical Statistics and InformaticsMayo ClinicRochesterUSA

Personalised recommendations